Company news

Lipocine Inc. news in 2025

Lipocine Inc.'s news releases, calls and decks from 2025, newest first.

View company

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

December 16, 2025

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

November 18, 2025

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

November 6, 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

November 4, 2025

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

September 30, 2025

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 5, 2025

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

August 26, 2025

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

August 5, 2025

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

June 26, 2025

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

June 23, 2025

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

June 9, 2025

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

March 26, 2025

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

March 13, 2025

Lipocine Announces FDA Labeling Changes for Testosterone Products

March 12, 2025

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

February 5, 2025

Decks in 2025